Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FolateImmune therapy - Endocyte/Purdue University

Drug Profile

FolateImmune therapy - Endocyte/Purdue University

Alternative Names: Folate-conjugated vaccine - Endocyte

Latest Information Update: 31 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Endocyte; Purdue University
  • Developer Endocyte
  • Class Cancer vaccines; Conjugate vaccines; Fluoresceins; Haptens; Imaging agents
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Renal cancer

Most Recent Events

  • 21 Dec 2018 Endocyte has been acquired by Novartis
  • 17 Dec 2013 Discontinued - Phase-I for Renal cancer in USA (SC)
  • 11 Feb 2009 The phase II trial is discontinued due to a lower than expected rate of accrual but phase I trials continue in renal cell carcinoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top